Victory Capital Management
ITCI

Victory Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Victory Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,938
Closed -$1.57M – 2575
2025
Q1 		$1.57M Sell
11,938
-50,261
-81% -$6.26M ﹤0.01% 1599
2024
Q4 		$5.19M Sell
62,199
-1,543
-2% -$127K 0.01% 1258
2024
Q3 		$4.66M Sell
63,742
-4,397
-6% -$330K ﹤0.01% 1285
2024
Q2 		$4.67M Buy
68,139
+4,674
+7% +$324K ﹤0.01% 1258
2024
Q1 		$4.39M Sell
63,465
-2,491
-4% -$171K ﹤0.01% 1266
2023
Q4 		$4.72M Sell
65,956
-1,523
-2% -$87.6K 0.01% 1245
2023
Q3 		$3.51M Sell
67,479
-818
-1% -$47.7K ﹤0.01% 1273
2023
Q2 		$4.32M Sell
68,297
-1,234
-2% -$76.9K ﹤0.01% 1231
2023
Q1 		$3.77M Sell
69,531
-38,349
-36% -$1.85M ﹤0.01% 1254
2022
Q4 		$5.71M Sell
107,880
-187,515
-63% -$9.4M 0.01% 1178
2022
Q3 		$13.7M Sell
295,395
-839,455
-74% -$43.9M 0.02% 956
2022
Q2 		$64.8M Buy
1,134,850
+202,528
+22% +$11.5M 0.07% 364
2022
Q1 		$56.9M Buy
+932,322
New +$48.4M 0.06% 470

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Victory Capital Management's ITCI Position: Q2 2025 in Review

Victory Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 11,938 shares — an estimated $1.57M sold.

Victory Capital Management first reported a position in ITCI in Q1 2022 and held it in 13 quarters. The position peaked at $64.8M in Q2 2022. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Victory Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Victory Capital Management sold 11,938 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $1.57M.
  • Victory Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 13 quarters.
  • Victory Capital Management's Intra-Cellular Therapies Inc. position peaked at $64.8M in Q2 2022.
  • 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Victory Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.